Guadalupe Zamora
Family Medicine · Austin, TXNPI 1588795348
Payments from drug & device makers
Across 376 payments — averaging $158.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk AS$54K
- AbbVie$748
- Lilly USA, LLC$718
- Novo Nordisk$563
- Pfizer$495
- AstraZeneca$438
- plus $3K from 30 others
What the payments were for
- Food & beverage$5,55898%
- Education$280%
- Gifts$591%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk AS | 53 | $53,818 |
| AbbVie(2 entities) | 51 | $748 |
| Lilly USA, LLC | 47 | $718 |
| Novo Nordisk | 29 | $563 |
| Pfizer | 24 | $495 |
| AstraZeneca | 23 | $438 |
| Boehringer Ingelheim | 18 | $348 |
| Mannkind Corporation | 14 | $260 |
| Sanofi-aventis U.S. LLC | 17 | $230 |
| Kowa Pharmaceuticals America, Inc. | 11 | $194 |
| Otsuka America Pharmaceutical, Inc. | 11 | $182 |
| Exact Sciences | 8 | $169 |
| Merck | 5 | $144 |
| Clarus Therapeutics Inc. | 7 | $144 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 8 | $117 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $100 |
| Astellas Pharma US Inc | 4 | $74 |
| Corcept Therapeutics | 4 | $73 |
| Idorsia Pharmaceuticals US Inc | 4 | $73 |
| Gilead | 4 | $66 |
| Amgen(2 entities) | 3 | $50 |
| Supernus Pharmaceuticals, Inc. | 3 | $47 |
| Dexcom, Inc. | 2 | $46 |
| Aytu Biopharma, Inc. | 3 | $45 |
| Abbott | 2 | $43 |
| GSK | 3 | $43 |
| Genentech USA, Inc. | 2 | $41 |
| Arbor Pharmaceuticals, Inc. | 2 | $32 |
| Sebela Pharmaceuticals Inc. | 2 | $29 |
| Bayer | 1 | $25 |
| Azurity Pharmaceuticals, Inc. | 1 | $24 |
| Sanofi Pasteur Inc. | 1 | $22 |
| Eisai Inc. | 1 | $20 |
| Johnson & Johnson | 1 | $15 |
| Tolmar, Inc. | 1 | $14 |
| Novartis | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- STEGLATRO$102
How this compares
$59,463 in reported general payments places this provider in the 95th percentile of 8,760 family medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 45 | $49,586 |
| OzempicSemaglutide | 35 | $46,832 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 13 | $24,054 |
| FarxigaDapagliflozin Propanediol | 17 | $22,399 |
| JardianceEmpagliflozin | 12 | $20,057 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 13 | $15,215 |
| EliquisApixaban | 16 | $14,613 |
| LinzessLinaclotide | 11 | $6,977 |
| TradjentaLinagliptin | 12 | $6,584 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 13 | $4,373 |
| Megestrol Acetate | 15 | $2,939 |
| Celecoxib | 62 | $2,844 |
| Dexlansoprazole DrDexlansoprazole | 14 | $2,663 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 17 | $2,555 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 125 | $2,288 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimSynjardy Xr, Jardiance, Tradjenta | $348 | $50,69437 claims |
| Lilly USA, LLCMounjaro | $718 | $49,58645 claims |
| Novo NordiskOzempic | $563 | $46,83235 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $438 | $37,61430 claims |
| PfizerEliquis | $495 | $14,61316 claims |
| AbbVieLinzess | $748 | $6,97711 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,760 family medicine providers in Texas.
Other family medicine in Austin
- Cynthia BrinsonAustin$13.9M
- Gregg LucksingerAustin$11.4M
- Faith HolmesAustin$7.5M
- Gretchen CrookAustin$4.4M
- Matthew BrimberryAustin$3.8M
- Nomita KimAustin$3.3M
- Douglas DenhamSan Antonio$68.5M
- Vicki MillerPasadena$58.3M
- Hareshkumar BogharaDesoto$30.3M
- Earl MartinTomball$30.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.